Cogent Biosciences price target raised to $15 from $13 at Citi

Citi raised the firm’s price target on Cogent Biosciences to $15 from $13 and keeps a Buy rating on the shares after meeting with management. The company highlighted bezuclastinib’s differentiated characteristics, including its high selectivity, that could allow for best-in-class profile, the analyst tells investors in a research note. The firm thinks the Street continues to underappreciate Cogent’s potential in non-advanced systemic mastocytosis and gastrointestinal stromal tumors.